City of Hope | Strategic Alliance Partners

June 01, 2019

Daphne B. Stewart, MD, discusses the progress that has been made with immunotherapy in ovarian cancer, provides insight into the focus on combination therapy with checkpoint inhibitors, and explains the impact of negative trials on the field.

May 31, 2019

Stephen J. Lee, MD, discusses the trials that have added to existing controversies regarding the optimal management of patients with newly diagnosed advanced ovarian cancer and highlights best practices for deciding between the approaches.

May 24, 2019

Joanne Mortimer, MD, associate director for Education and Training, Comprehensive Cancer Center, Baum Family Professor in Women’s Cancers, vice chair and professor, Department of Medical Oncology and Therapeutics Research, director, Women’s Cancer Programs, and breast cancer oncologist, City of Hope, discusses brain metastases in women with HER2-positive breast cancer.

May 24, 2019

Ernest S. Han, MD, PhD, FACOG, discusses the role of HIPEC in advanced ovarian cancer at the time of interval debulking, as well as anticipated research examining its use at time of primary debulking.

May 09, 2019

Joanne Mortimer, MD, discusses key facets of treatment for patients with early and metastatic HER2-positive breast cancer.

May 09, 2019

Daphne B. Stewart, MD, highlights the pivotal trials evaluating CDK4/6 inhibitors and what unanswered questions remain with this class of agents.

May 08, 2019

Laura Kruper, MD, MS, discusses outstanding questions within the context of the current management of the axilla.

May 07, 2019

Sayeh Lavasani, MD, MS, discusses the application of gene assays in the management of patients with hormone receptor-positive breast cancer, as well as ongoing research in this space.

May 06, 2019

Yuan Yuan, MD, PhD, discusses how treating physicians are optimizing novel agents for patients with metastatic triple-negative breast cancer.

May 03, 2019

Joanne Mortimer, MD, associate director for Education and Training, Comprehensive Cancer Center, Baum Family Professor in Women’s Cancers, vice chair and professor, Department of Medical Oncology & Therapeutics Research, director, Women’s Cancer Programs, City of Hope, discusses adjuvant therapy in early-stage HER2-positive breast cancer.

May 02, 2019

Scott Glaser, MD, assistant clinical professor of radiation oncology, City of Hope, discusses strategies for managing radiation-induced adverse events in patients with early-stage breast cancer.

April 18, 2019

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses the use of immunotherapy in patients with microsatellite stable (MSS) colon cancer.

April 18, 2019

City of Hope recently received $7.5 million in grant awards to study a rare type of blood cancer that affects the skin: cutaneous T cell lymphoma.

April 11, 2019

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses the use of regional therapy in the treatment of patients with colorectal cancer (CRC).

April 10, 2019

The recent technological advances in medicine and related fields have encouraged a belief among many that there is little technology will not be able to accomplish in improving cancer-related clinical outcomes, but it must be acknowledged that clinical medicine and cancer biology are extremely complex arenas.

March 07, 2019

Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses the emergence of molecular signatures in patients with renal cell carcinoma (RCC).

March 07, 2019

Tanya B. Dorff, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research, and head of the genitourinary cancers program at City of Hope, discusses the use of PARP inhibitors in prostate cancer.

February 23, 2019

Vincent Chung, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, director of the Phase I Program, City of Hope, discusses the COMPASS trial in pancreatic cancer.

February 22, 2019

An international leader in finding new, innovative treatments for lymphoma patients, City of Hope announced today that it has received its third lymphoma Specialized Programs of Research Excellence grant from the National Cancer Institute.

February 21, 2019

Byrne Lee, MD, chief, Upper GI and Mixed Tumor Surgery Service, associate professor of surgical oncology, City of Hope, discusses the benefit of cytoreductive surgery in the treatment of patients with metastatic colorectal cancer (mCRC).